MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
14.50
-0.97
-6.27%
After Hours: 14.55 +0.05 +0.34% 19:53 10/26 EDT
OPEN
15.49
PREV CLOSE
15.47
HIGH
15.62
LOW
14.37
VOLUME
4.78M
TURNOVER
--
52 WEEK HIGH
29.23
52 WEEK LOW
12.07
MARKET CAP
11.60B
P/E (TTM)
-12.9557
1D
5D
1M
3M
1Y
5Y
1D
Goldman Sachs Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
TipRanks · 16h ago
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Pfizer (PFE) and Summit Therapeutics (SMMT)
TipRanks · 20h ago
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Summit Therapeutics (SMMT)
TipRanks · 21h ago
Lunit And Summit Collaborate On AI-Powered Biomarker Discovery For Ivonescimab
NASDAQ · 21h ago
Summit Therapeutics: Buy Rating Reaffirmed on Durable HARMONi-GI1 Survival Data; $43 Price Target Maintained
TipRanks · 21h ago
Weekly Report: what happened at SMMT last week (1019-1023)?
Weekly Report · 22h ago
Summit, Lunit announce research agreement to evaluate Lunit SCOPE IO
TipRanks · 1d ago
Summit’s partner announces results from Phase III HARMONi-GI1 study
TipRanks · 1d ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.